Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

74.51
-0.6400-0.85%
Post-market: 73.90-0.6100-0.82%18:20 EST
Volume:2.33M
Turnover:174.22M
Market Cap:14.36B
PE:-17.81
High:75.61
Open:74.96
Low:73.95
Close:75.15
52wk High:75.61
52wk Low:25.34
Shares:192.71M
Float Shares:151.20M
Volume Ratio:1.41
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1844
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-43.47%
PB:-7.43
PE(LYR):-25.88

Loading ...

Stock Track | BridgeBio Pharma Soars 5.12% Ahead of Crucial Phase 3 Trial Results Announcement

Stock Track
·
Oct 29

BridgeBio Pharma to Announce Phase 3 CALIBRATE Trial Results for Encaleret in ADH1

Reuters
·
Oct 29

BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 28

BridgeBio price target raised to $76 from $58 at BofA

TIPRANKS
·
Oct 28

BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $80 From $70

THOMSON REUTERS
·
Oct 28

BridgeBio Pharma Up Over 18%, on Track for Highest Close Since July 2021 -- Data Talk

Dow Jones
·
Oct 28

BUZZ-U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm

Reuters
·
Oct 28

Piper Sandler Adjusts Price Target on BridgeBio Pharma to $80 From $68, Maintains Overweight Rating

MT Newswires Live
·
Oct 27

BridgeBio Pharma Inc : Piper Sandler Raises Target Price to $80 From $68

THOMSON REUTERS
·
Oct 27

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $68 From $64

THOMSON REUTERS
·
Oct 27

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
Oct 27

BridgeBio Says Study of Muscular Dystrophy Treatment Showed Motor, Pulmonary Improvements

MT Newswires Live
·
Oct 27

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Keysight Technologies, Keurig Dr Pepper

Reuters
·
Oct 27

S&P 500 Futures Climb In Premarket Trading; Avidity Biosciences, BridgeBio Pharma Lead

Dow Jones
·
Oct 27

BRIEF-BridgeBio Says Fortify Phase 3 Study Meets All Primary & Secondary Interim Analysis Endpoints

Reuters
·
Oct 27

BridgeBio: to File Nda for Approval With FDA in H1 2026

THOMSON REUTERS
·
Oct 27

BridgeBio's genetic muscle disorder drug meets all goals in late-stage trial

Reuters
·
Oct 27

BridgeBio Reports Positive Phase 3 Results for Small Molecule Bbp-418 in Lgmd2i/R9 Fortify Study

THOMSON REUTERS
·
Oct 27

BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 for KRAS Mutant and HER2+ Cancers

Reuters
·
Oct 26

BridgeBio Pharma Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 25